Leerink Partnrs Has Pessimistic Outlook of VYGR Q3 Earnings

Key Points

• Voyager Therapeutics reported a Q3 EPS of ($0.57), missing estimates by $0.09, with revenue of $5.20 million versus expectations of $9.50 million.
• Equity analysts from Leerink Partners have lowered their Q3 2025 EPS forecast for Voyager Therapeutics to ($0.55), down from ($0.45).
• Despite the recent setbacks, Voyager Therapeutics holds an average buy rating among analysts with a price target of $13.25.

Voyager Therapeutics, Inc. (NASDAQ:VYGR - Free Report) - Equities researchers at Leerink Partnrs cut their Q3 2025 earnings per share (EPS) estimates for Voyager Therapeutics in a report issued on Wednesday, August 6th. Leerink Partnrs analyst L. Nsongo now forecasts that the company will post earnings per share of ($0.55) for the quarter, down from their previous forecast of ($0.45). The consensus estimate for Voyager Therapeutics' current full-year earnings is ($0.91) per share. Leerink Partnrs also issued estimates for Voyager Therapeutics' Q4 2025 earnings at ($0.58) EPS, FY2025 earnings at ($2.23) EPS, FY2026 earnings at ($0.48) EPS, FY2027 earnings at ($0.91) EPS, FY2028 earnings at ($0.33) EPS and FY2029 earnings at ($1.03) EPS.

Separately, Wedbush lowered their price target on Voyager Therapeutics from $9.00 to $8.00 and set an "outperform" rating on the stock in a report on Thursday, August 7th. One analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $13.25.

Voyager Therapeutics Stock Up 9.9%

NASDAQ VYGR traded up $0.34 during trading hours on Monday, reaching $3.73. The company's stock had a trading volume of 890,018 shares, compared to its average volume of 525,242. The firm's 50-day moving average price is $3.23 and its 200-day moving average price is $3.60. Voyager Therapeutics has a 1 year low of $2.64 and a 1 year high of $8.27. The company has a market capitalization of $206.73 million, a price-to-earnings ratio of -2.01 and a beta of 0.90.

Voyager Therapeutics (NASDAQ:VYGR - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.57) EPS for the quarter, missing the consensus estimate of ($0.48) by ($0.09). Voyager Therapeutics had a negative return on equity of 37.65% and a negative net margin of 253.49%. The company had revenue of $5.20 million during the quarter, compared to the consensus estimate of $9.50 million.

Hedge Funds Weigh In On Voyager Therapeutics

A number of institutional investors have recently bought and sold shares of the business. Wells Fargo & Company MN grew its holdings in Voyager Therapeutics by 3.7% in the fourth quarter. Wells Fargo & Company MN now owns 66,718 shares of the company's stock valued at $378,000 after purchasing an additional 2,400 shares during the period. Tower Research Capital LLC TRC grew its holdings in Voyager Therapeutics by 133.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 5,383 shares of the company's stock valued at $31,000 after purchasing an additional 3,077 shares during the period. Privium Fund Management B.V. lifted its position in shares of Voyager Therapeutics by 16.6% in the second quarter. Privium Fund Management B.V. now owns 25,241 shares of the company's stock valued at $79,000 after acquiring an additional 3,596 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Voyager Therapeutics by 0.4% in the fourth quarter. Geode Capital Management LLC now owns 1,084,238 shares of the company's stock valued at $6,149,000 after acquiring an additional 4,729 shares in the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Voyager Therapeutics in the fourth quarter valued at approximately $29,000. 48.03% of the stock is owned by hedge funds and other institutional investors.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.